-
Mashup Score: 14'24 Move for MDS: Tampa - 1 month(s) ago
Move for MDS 2023
Source: secure.qgiv.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 53Triple-Negative Myelofibrosis: Disease Features, Response to Treatment and Outcomes - 1 month(s) ago
MicroabstractTriple-negative myelofibrosis (MF) constitutes a distinct disease subset marked by aggressive clinical features, higher rates of leukemic transformation, shorter duration of response to ruxolitinib and poor survival. Mutations affecting epigenetic modification, RNA splicing and signaling likely drive its hostile course and may account for suboptimal responses to JAK inhibition.
Categories: General Medicine News, Hem/OncsTweet-
Our recent manuscript addressing Triple-Negative Myelofibrosis https://t.co/g4skBV6fdI great work by @LeafOnc @KuykendallMd @MoffittNews
-
-
Mashup Score: 53Triple-Negative Myelofibrosis: Disease Features, Response to Treatment and Outcomes - 1 month(s) ago
MicroabstractTriple-negative myelofibrosis (MF) constitutes a distinct disease subset marked by aggressive clinical features, higher rates of leukemic transformation, shorter duration of response to ruxolitinib and poor survival. Mutations affecting epigenetic modification, RNA splicing and signaling likely drive its hostile course and may account for suboptimal responses to JAK inhibition.
Categories: General Medicine News, Hem/OncsTweet-
Our recent manuscript addressing Triple-Negative Myelofibrosis https://t.co/g4skBV6fdI great work by @LeafOnc @KuykendallMd @MoffittNews
-
-
Mashup Score: 53
The patterns of low risk myelodysplastic syndrome (MDS) progression, and the clinical and molecular features of those patterns are not well described. We divided our low risk (LR) MDS patients (n=1914) into 4 cohorts: 1) Patients who remained LR-MDS (LR-LR; n=1300; 68%), 2) Patients who progressed from LR to HR MDS (LR-HR) without AML transformation (n=317; 16.5%), 3) Patients who progressed from LR to HR MDS and then AML (LR-HR-AML; n=124; 6.5%), 4) Patients who progressed from LR MDS to AML directly (LR-AML; n=173; 9%). Risk factors for progression included male gender, low absolute neutrophil count (ANC), low platelet count, high bone marrow (BM) blasts, ferritin >1000 mcg/L, albumin
Source: haematologica.orgCategories: General Medicine News, Hem/OncsTweet-
Early View | Haematologica https://t.co/N5HmqZNdnk our paper addressing pattern of LRMDS progression. Majority don’t progress and molecular signatures can identify direct AML progression. @AkritiGJain @md_padron @lancet @drsomedeb @LeafOnc @KuykendallMd @onyee_c @KendraSweetMD
-
-
Mashup Score: 114
Imetelstat offers a novel mechanism of action with durable transfusion independence (approximately 1 year) and disease-modifying activity for heavily transfused patients with LR-MDS who are not responding to or are ineligible for ESAs.
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet-
Honored to be co-senior author on Imetelstat for lower-risk MDS The Lancet manuscript https://t.co/V6HgddJyIy collaborative effort w great colleagues , hope next rx to approve for MDS. @Dr_AmerZeidan @UwePlatzbecker @Santin13Valeria @MikkaelSekeres @madanatyazan @madicamp
-
-
Mashup Score: 109
Imetelstat offers a novel mechanism of action with durable transfusion independence (approximately 1 year) and disease-modifying activity for heavily transfused patients with LR-MDS who are not responding to or are ineligible for ESAs.
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet-
Honored to be co-senior author on Imetelstat for lower-risk MDS The Lancet manuscript https://t.co/V6HgddJyIy collaborative effort w great colleagues , hope next rx to approve for MDS. @Dr_AmerZeidan @UwePlatzbecker @Santin13Valeria @MikkaelSekeres @madanatyazan @madicamp
-
-
Mashup Score: 0Assessment and validation of the molecular international prognostic scoring system for myelodysplastic syndromes - Leukemia - 1 year(s) ago
The Molecular International Prognostic Scoring System (IPSS-M) is a novel risk stratification model for myelodysplastic syndromes (MDS) that builds on the IPSS and IPSS-R by incorporating mutational data. The model showed improved prognostic accuracy over the IPSS-R across three endpoints: overall survival (OS), leukemia-free survival (LFS) and leukemic transformation. This study aimed to…
Source: NatureCategories: Hem/Oncs, Latest HeadlinesTweet-
Our latest paper validating IPSS-M in one of the largest cohorts published in leukemia journal. Kudos to super fellow Luis Aguirre and the whole MDS team @LeafOnc @MoffittNews @MoffittResearch @md_padron https://t.co/vNEeQgJBhQ
-
-
Mashup Score: 1MPN-MDS US - 1 year(s) ago
Kimpton Hotel Palomar Phoenix, Arizona Save The Date: April 28-29 The Co-chairs of the 2023 MPN-MDS US Focus Meeting are: Prithviraj Bose, MDMD…
Source: mpn-mds2023.md-education.comCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @_MDEducation: Join us on April 28-29 in Phoenix or virtually. 𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿 𝗻𝗼𝘄: https://t.co/PQIoUBWoXD #MPN #MDS #hematology #mdeducat…
-
-
Mashup Score: 1👯 Who is your Twitter twin? - 1 year(s) ago
Discover your twin on Twitter now!
Source: ToasteedCategories: Hem/Oncs, Latest HeadlinesTweet-
Such a privilege and joy to be the @beatalleukemia Twitter twin. Who is your Twitter twin? 👯 @Ramikomrokji = @beatalleukemia Ramikomrokji and beatalleukemia are Twitter twins! #twitterTwin #toasteed https://t.co/gSIUqYWNQF
-
-
Mashup Score: 8Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes - 1 year(s) ago
Rami S. Komrokji, Luis E. Aguirre, Najla Al-Ali, Onyee Chan, Zhuoer Xie, Andrew T. Kuykendall, Kendra L Sweet, Jeffrey E. Lancet, Eric Padron, David A. Sallman;
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Our latest paper providing first proof of principle. Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes https://t.co/iwzH9C9tUY
-
Come and join us '24 Move for MDS: Tampa’ honored to be hosting in Tampa and helping MDS research fundraising @MoffittNews @MDSFoundation https://t.co/OkHDvwfn5F #